Ken Griffin 2seventy Bio, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in 2seventy Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,800 shares of TSVT stock, worth $119,000. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,800

Previous 17,300 37.57%

Holding current value

$119,000

Previous $50,000 134.0%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$2.89 - $5.21 $35,260 - $63,567	12,201 Added 10428.21%	12,318 $36,000
Q3 2024 Nov 14, 2024	SELL	$3.85 - $5.05 $72,714 - $95,379	-18,887 Reduced 99.38%	117 $0
Q2 2024 Aug 14, 2024	SELL	$3.6 - $5.79 $106,250 - $170,886	-29,514 Reduced 60.83%	19,004 $73,000
Q1 2024 May 15, 2024	SELL	$3.09 - $6.0 $288,516 - $560,226	-93,371 Reduced 65.81%	48,518 $259,000
Q4 2023 Feb 14, 2024	SELL	$1.57 - $4.58 $377,329 - $1.1 Million	-240,337 Reduced 62.88%	141,889 $605,000
Q3 2023 Nov 14, 2023	BUY	$3.14 - $11.2 $559,287 - $1.99 Million	178,117 Added 87.27%	382,226 $1.5 Million
Q2 2023 Aug 14, 2023	SELL	$8.45 - $12.48 $18.3 Million - $27 Million	-2,162,130 Reduced 91.37%	204,109 $2.07 Million
Q1 2023 May 15, 2023	BUY	$9.21 - $14.98 $19.4 Million - $31.5 Million	2,104,527 Added 804.14%	2,366,239 $24.1 Million
Q4 2022 Feb 14, 2023	BUY	$8.57 - $17.0 $1.25 Million - $2.48 Million	146,054 Added 126.28%	261,712 $2.45 Million
Q3 2022 Nov 14, 2022	BUY	$12.56 - $17.54 $190,510 - $266,046	15,168 Added 15.09%	115,658 $1.68 Million

Others Institutions Holding TSVT

# of Institutions

153

Shares Held

47.5M

Call Options Held

116K

Put Options Held

7.5K

View Full List

About 2seventy bio, Inc.

Ticker TSVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,873,600
Market Cap $189M
Description
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a col...

More about TSVT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account